Sponsor:
GV20 Therapeutics
Code:
NCT05669430
Conditions
Solid Tumor, Adult
Refractory Cancer
Endometrial Carcinoma (EC)
Squamous Head and Neck Carcinoma
pMMR/MSS Adenocarcinoma of the Colon or Rectum
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
GV20-0251
GV20-0251
GV20-0251 and Pembrolizumab [KEYTRUDA®]
GV20-0251 and Pembrolizumab [KEYTRUDA®]
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-25. This information was provided to ClinicalTrials.gov by GV20 Therapeutics on 2025-02-13.